Vertex lab coat

FDA Approves SYMDEKO® (tezacaftor/ivacaftor and ivacaftor) for an Expanded Indication

Vertex scientist wearing goggles

Vertex Selects Triple Combination Regimen for Potential Global Regulatory Approvals in Cystic Fibrosis

Female Vertex scientist looking through a microscope

Vertex Shares Data from its Cystic Fibrosis Portfolio and Investigational Pipeline at ECFS Conference

Biotechnology to Create Transformative Medicines

At Vertex, we're relentless in our pursuit of medical research to create transformative medicines for people with serious and life-threatening diseases, like cystic fibrosis.

pipeline and medicine

Vertex has more than a dozen ongoing research programs focused on the underlying mechanisms of other serious diseases.

working here

At Vertex, we have some of the industry's best and brightest people helping us achieve our mission of discovering transformative medicines to help people with serious diseases, like cystic fibrosis. 


FDA Approves SYMDEKO® (tezacaftor/ivacaftor and ivacaftor) to Treat the Underlying Cause of CF in Children Ages 6-11 Years with Certain Mutations in the CFTR Gene

Follow Us for Updates